WHAT IS CLAIMED IS:

1. A method for producing a recombinant Von Willebrand Factor (rVWF) composition, the method comprising the steps of:

(a) providing a basal cell culture media;

(b) supplementing the basal cell culture media with copper to provide a final copper concentration of at least 2.4 µg/L;

(c) providing one or more cells comprising a nucleic acid encoding a rVWF protein;

(d) culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant, wherein an $NH4^+$ content of the cell culture supernatant is maintained at a concentration below 10 mM; and

(e) recovering at least a portion of the culture supernatant,

wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/µg rVWF.

2. The method of claim 1, further comprising the step of supplementing the basal cell culture media with a hydrolysate prior to culturing the one or more cells.

3. The method of claim 2, wherein the hydrolysate is a plant hydrolysate.

4. The method of claim 3, wherein the hydrolysate is a soy hydrolysate.

5. The method according to any one of claims 1 to 4, wherein the basal cell culture media is an animal protein free culture media.

6. The method according to any one of claims 1 to 4, wherein the basal cell culture media is a protein free culture media.

7. The method according to any one of claims 1 to 6, wherein the basal cell culture media is a chemically defined culture media.

8. The method according to any one of claims 1 to 7, wherein the final copper concentration of the copper supplemented basal cell culture media is at least 4 μg/L copper.

9. The method according to any one of claims 1 to 8, wherein the final copper concentration of the copper supplemented basal cell culture media is between 2.4 μg/L and 20 μg/L copper.

10. The method according to any one of claims 1 to 9, wherein the copper supplementing the basal cell culture media is provided as a copper salt, a copper chelate, or a combination thereof.

11. The method of claim 10, wherein the copper salt is selected from the group consisting of copper sulfate, copper acetate, copper carbonate, copper chloride, copper hydroxide, copper nitrate, and copper oxide.

12. The method according to any one of claims 1 to 11, wherein the one or more cells are mammalian cells.

13. The method of claim 12, wherein the mammalian cells are CHO cells.

14. The method according to any one of claims 1 to 13, wherein culturing the one or more cells comprises batch cultivation of the cells.

15. The method according to any one of claims 1 to 13, wherein culturing the one or more cells comprises continuous cultivation of the cells.

16. The method of claim 15, wherein the continuous cultivation of cells is performed in chemostatic mode.

17. The method of claim 15, wherein the continuous cultivation of cells is performed in perfusion mode.

18. The method according to any one of claims 1 to 17, wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media.

19. The method according to any one of claims 1 to 18, wherein the cell density is maintained at less than $2.5x10^6$ cells per mL during the step of culturing the one or more cells.

20. The method of claim 19, wherein the cell density is maintained at less than $2.0x10^6$ cells per mL during the step of culturing the one or more cells.

21. The method of claim 19, wherein the cell density is maintained at less than $1.5x10^6$ cells per mL during the step of culturing the one or more cells.

22. The method according to any one of claims 1 to 21, wherein the step of recovering at least a portion of the culture supernatant comprises filtration or centrifugation to remove cells from the portion of culture supernatant.

23. The method according to any one of claims 1 to 22, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 40 mU/μg rVWF.

24. The method of claim 23, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 50 mU/μg rVWF.

25. The method of claim 23, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 60 mU/μg rVWF.

26. The method of claim 23, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 70 mU/μg rVWF.

27. The method of claim 23, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 80 mU/μg rVWF.

28. The method according to any one of claims 1 to 27, wherein at least 10% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

29. The method according to any one of claims 1 to 27, wherein at least 20% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

30. The method according to any one of claims 1 to 27, wherein at least 30% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

31. The method according to any one of claims 1 to 30, wherein the supernatant contains high molecular weight VWF multimers of 14 to 22 dimers.

~~32. The method according to any one of claims 1 to 31, wherein the NH_4^+ content of the cell culture supernatant is maintained at a concentration below 10 mM.~~

~~33~~32. The method of claim ~~32~~ 1, wherein the NH_4^+ content of the cell culture supernatant is maintained at a concentration below 4 mM.

~~34~~33. The method according to any one of claims 1 to ~~33~~ 32, wherein rVWF is co-expressed with recombinant Factor VIII (rFVIII).

~~35~~34. The method of claim ~~34~~ 33, further comprising a step of purifying rVWF away from at least 50% of the rFVIII present in the recovered supernatant.

~~36~~35. The method of claim ~~35~~ 34, wherein the ratio of rVWF to rFVIII after the purification step is at least 10:1.

~~37~~36. The method according to any one of claims 1 to ~~36~~ 35, wherein the method further comprises a rVWF enrichment step.

~~38~~37. A cell culture supernatant comprising recombinant Von Willebrand Factor (rVWF), wherein the supernatant is prepared by a method according to any one of the preceding claims.

~~39~~38. A cell culture supernatant comprising recombinant Von Willebrand Factor (rVWF), wherein at least 20% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

~~40~~39. A cell culture supernatant comprising recombinant Von Willebrand Factor (rVWF), wherein the supernatant contains at least 0.5 IU ristocetin cofactor activity per mL.

~~41~~40. A recombinant Von Willebrand Factor (rVWF) composition prepared by a method according to any one of claims 1 to ~~37~~ 36.

~~42~~41. The composition of claim ~~41~~ 40, wherein the composition further comprises recombinant Factor VIII (rFVIII).

~~43~~42. The composition of claim ~~42~~ 41, wherein the ratio of rVWF to rFVIII is at least 10:1.

~~44~~43. The composition of claim ~~42~~41 or ~~43~~ 42, wherein the composition is formulated for pharmaceutical administration.

~~45~~44. The composition according to any one of claims ~~42~~41 to ~~44~~ 43, wherein the composition is formulated for intravenous administration.